EGFR and neoplasm: In contrast to other anti-EGFR antibodies in clinical development or approved by the FDA (e.g. Erbitux®) that also bind normal EGFR present on normal human skin and liver, ch806 is a novel direct-killing anticancer antibody with specificity only for the tumour it is targeting, and not normal human cells.